



# CITURGIA BIOCHEMICALS LIMITED

**Regd. Office:** 6/C, Ostwal Park Building No. 4, Chsl, Near Jesal Park, Jain Temple,  
Bhayandar East, Thane-401105, Maharashtra. **CIN:** L24100MH1974PLC017773  
**Phone:** - 91 9650923555, **Website:** [www.citurgiabio.com](http://www.citurgiabio.com); **E-mail id:** citurgia\_bio@yahoo.com

**Date: 20.01.2020**

**To,**

**BSE Limited**  
**P J Towers, Dalal Street**  
**Mumbai - 400001**  
**Scrip Code: 506373,**  
**Scrip ID: CITURGIA**


**Sub: Submission of Revised Unaudited Financial Results for Quarter and half year ended 30<sup>th</sup> September, 2019.**

Dear Sir/Madam,

Please find enclosed herewith Revised Unaudited Financial Results for the Quarter and half year ended 30<sup>th</sup> September, 2019 along with Limited Review Report issued by the statutory auditor for the quarter and half year ended 30<sup>th</sup> September, 2019 and Cash Flow statement as on 30.09.2019.

We request you to kindly take the above information on record.

For CITURGIA BIOCHEMICALSLIMITED


  
**AKSHOD KUMAR SHARMA**  
**WHOLE TIME DIRECTOR**  
**DIN: 02112607**

**PART-I Statement Of Unaudited Financial Results For The Quarter and Half Year Ended 30.09.2019**

Particulars		Quarter Ended			Period Ended		Year Ended
		3 Months ended 30/09/2019	Preceding 3 months ended 30/06/2019	Corresponding 3 months ended 30/09/2018	Year to Figure for current year ended 30.09.2019	Year to Figure for previous year ended 30.09.2018	Current Ended 31/03/2019
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I.	Total Income form Operations	-	-	-	-	-	-
II.	Other Income	-	-	-	-	-	-
III.	<b>Total Revenue (I+II)</b>	-	-	-	-	-	-
IV.	<b>Expenses</b>						
	a) Cost of Materials consumed	-	-	-	-	-	-
	b) Purchase of Stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, WIP and stock in trade	-	-	-	-	-	-
	d) Employee benefits expenses	3.45	3.45	8.02	6.89	11.33	13.34
	e) Depreciation and amortization expenses	6.92	6.92	16.04	13.84	24.07	32.09
	f) Other expenses	0.22	0.10	6.13	0.32	11.35	10.76
	<b>Total Expenses</b>	<b>10.59</b>	<b>10.47</b>	<b>30.20</b>	<b>21.05</b>	<b>46.75</b>	<b>56.18</b>
V	Profit/(Loss) before exceptional and extraordinary items and tax (III-V)	<b>(10.59)</b>	<b>(10.47)</b>	<b>(30.20)</b>	<b>(21.05)</b>	<b>(46.75)</b>	<b>(56.18)</b>
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(Loss) before extraordinary items and tax (VI-VII)	(10.59)	(10.47)	(30.20)	(21.05)	(46.75)	(56.18)
VIII	Extraordinary items	-	-	-	-	-	-
IX	Profit/(Loss) before tax (VIII-IX)	(10.59)	(10.47)	(30.20)	(21.05)	(46.75)	(56.18)
X	Tax expenses						
	a) Current Tax	-	-	-	-	-	-
	a) Income Tax Adjustment	-	-	-	-	-	-
	a) Deferred Tax Adjustment	-	-	-	-	-	-
	b) Deferred Tax Liabilities / (Assets)	-	-	-	-	-	-
XI	Profit (Loss) for the period from continuing operations (IX-X)	(10.59)	(10.47)	(30.20)	(21.05)	(46.75)	(56.18)
XII	Profit/(loss) from discontinuing operations	-	-	-	-	-	-
XIII	Tax expense of discontinuing operations	-	-	-	-	-	-
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-	-
XV	Profit (Loss) for the period (XI + XIV)	(10.59)	(10.47)	(30.20)	(21.05)	(46.75)	(56.18)
XVI	Other Comprehensive Income						
	A (i) Items that will not be	-	-	-	-	-	-

	reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	(10.59)	(10.47)	(30.20)	(21.05)	(46.75)	(56.18)
XVIII	Earnings per equity share (for continuing operation):						
	(1) Basic	0.001	(0.006)	0.0000	0.000	0.001	(0.021)
	(2) Diluted	0.001	(0.006)	0.0000	0.000	0.001	(0.021)
XIX	Earnings per equity share (for discontinued operation):						
	(1) Basic	0.001	(0.006)	0.0000	0.000	0.001	(0.021)
	(2) Diluted	0.001	(0.006)	0.0000	0.000	0.001	(0.021)
XX	Earning Per Share (for discontinued & continuing operations)						
	a) Basic	0.001	(0.006)	0.0000	0.000	0.001	(0.021)
	b) Diluted	0.001	(0.006)	0.0000	0.000	0.001	(0.021)

For CITURGIA BIOCHEMICALSLIMITED

  
**AKSHOD KUMAR SHARMA**  
**WHOLE TIME DIRECTOR**  
**DIN: 02112607**

**Date : 12.11.2019**

**Place : Mumbai**

**PART-II STATEMENT OF ASSETS AND LIABILITIES AS AT 30.09.2019**

S. No.	Particulars	(Rs. In lacs)	
		As at 30.09.2019	As at 31.03.2019
		Unaudited	Audited
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non- Current Assets</b>		
	(a) Property, Plant and Equipment	190.07	203.91
	(b) Capital Work-in-Progress	-	-
	(c) Other Intangible Assets	-	-
	(d) Financial Assets		
	(i) Investments	0.02	0.02
	(ii) Loan & Advances	198.70	201.10
	(iii) Other financial assets	-	-
	(e) Deferred tax assets (net)	-	-
	(f) Other Non-Current Assets	-	-
	<b>Total Non-Current Assets</b>	<b>388.79</b>	<b>405.02</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Inventories	806.63	806.63
	(b) Financial Assets		
	(i) Trade Receivables	-	-
	(ii) Cash and Bank Equivalents	6.73	11.49
	(iii) Bank balances other than (ii) above	-	-
	(iv) Loan & Advances	3.02	3.02
	(v) Investment	-	-
	(c) Other Current Assets	10.08	10.08
	<b>Total Current Assets</b>	<b>826.46</b>	<b>831.23</b>
	<b>TOTAL ASSETS</b>	<b>1,215.26</b>	<b>1,236.25</b>
	<b>EQUITY AND LIABILITIES</b>		
	<b>Equity</b>		
	(a) Equity Share Capital	2,641.91	2,641.91
	(b) Other Equity	-3,337.40	-3,316.35
	(c) Money received against share warrants	250.00	250.00
	<b>Total Equity</b>	<b>-445.49</b>	<b>-424.44</b>
<b>B</b>	<b>Liabilities</b>		
<b>1</b>	<b>Non-Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	644.96	644.96
	(b) Deferred Tax Liabilities (Net)	171.06	171.06
	(c) Other long Term Liabilities	11.73	11.73
	<b>Total Non-Current Liabilities</b>	<b>827.75</b>	<b>827.75</b>
<b>2</b>	<b>Current Liabilities</b>		

	(a) Financial Liabilities		
	(i) Borrowings	3.40	3.40
	(ii) Trade Payables	363.12	363.12
	(iii) Other Financial Liabilities	-	-
	(b) Other Current Liabilities	415.47	415.41
	(c) Provisions	51.01	51.01
	<b>Total Current Liabilities</b>	<b>833.00</b>	<b>832.95</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>1,215.26</b>	<b>1,236.25</b>

**NOTES :**


1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 12<sup>th</sup> November, 2019.

2. The previous period figures have been rearranged / regrouped, wherever necessary to confirm to current period classifications.

3. The financial results are subject to the Limited Review Report issued by the statutory auditors of the company.

4. The Financial Results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules there under in terms of Regulation 33 of SEBI (Listing and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

For CITURGIA BIOCHEMICALSLIMITED

  
AKSHOD KUMAR SHARMA  
WHOLE TIME DIRECTOR  
DIN: 02112607


**Date : 12.11.2019**

**Place : Mumbai**

<b>CASH FLOW STATEMENT</b>	<b>AMOUNT IN LAKHS</b>	
<b>Particulars</b>	<b>Year ended 30.09.2019</b>	<b>Year ended 31.03.2019</b>
<b><u>(A) CASH FLOW FROM OPERATING ACTIVITIES:-</u></b>		
1. Net profit before tax	(21.05)	(56.18)
<b>2. <u>Adjustment for:</u></b>		
<u>Add:</u> Depreciation & Amortisation Expenses	13.84	32.09
<u>Add:</u> Amortization Expenses / Written off	-	-
<u>Less:</u> Other Income	-	-
<b>Operating Profit before Working capital changes</b>	<b>(7.21)</b>	<b>(24)</b>
<b>3. <u>Working Capital Changes:</u></b>		
Decrease (Increase) in Trade & Other Receivables	-	-
Decrease (Increase) in Inventories	-	(2.72)
Decrease (Increase) in Other Current Assets	-	-
Decrease (Increase) in Other Non Current Assets	-	-
Increase (Decrease) in Trade & Other Payables	-	-
Increase (Decrease) in Current Liabilities & Provisions	-	7.75
Increase (Decrease) in Other Current Liabilities	0.05	-
<b>Net Changes in Working Capital</b>	<b>0.05</b>	<b>5</b>
<b><u>Cash Generated from Operations</u></b>	<b>(7.16)</b>	<b>(19)</b>
<b>Adjustment of Taxes</b>	-	-
<b>Net Cash Flow from Operating Activities (A)</b>	<b>(7.16)</b>	<b>(19)</b>
<b><u>(B.) CASH FLOW FROM INVESTING ACTIVITIES :</u></b>		
Purchase of Property, Plant & Equipment	-	-
<b><u>Non Current Financial Assets</u></b>		
(Increase) Decrease in Loans & Advances	2.40	1.5
<b><u>Current Financial Assets</u></b>		
(Increase) Decrease in Loans & Advances	-	-
Other Income	-	-
(Increase) Decrease in Current Investments	-	-
<b>Net Cash Flow from Investing Activities (B)</b>	<b>2.40</b>	<b>2</b>
<b><u>(C.) CASH FLOW FROM FINANCING ACTIVITIES :</u></b>		
Issue of share capital and Proceeds from Share Application Money	-	-
<b><u>Non Current Financial Assets</u></b>		
Increase / (Decrease) in Borrowings	-	3.0
<b><u>Current Financial Assets</u></b>		
Increase / (Decrease) in Borrowings	-	-
Increase in Preliminary Expenses	-	-
<b>Net Cash Flow from Financing Activities (C)</b>	-	<b>3.00</b>
<b>Net Increase / (Decrease) in Cash &amp; Cash</b>	<b>(4.76)</b>	<b>(14.56)</b>

<b>Equivalents ( A-B+C )</b>		
<b>Cash and cash equivalents at the beginning of the year / Period</b>	<b>11.49</b>	<b>26.05</b>
<b>Cash and cash equivalents at the end of the year/ Period</b>	<b>6.73</b>	<b>11.49</b>
<b>* Note: The above Cash Flow Statement has been prepared under "Indirect Method" as set out in the Accounting Standard</b>		

For CITURGIA BIOCHEMICALSLIMITED

  
**AKSHOD KUMAR SHARMA**  
**WHOLE TIME DIRECTOR**  
**DIN: 02112607**

**Date : 12.11.2019**  
**Place : Mumbai**



# **G.P. KESHRI & ASSOCIATES**

## **Chartered Accountants**

Head Office: A-215/5, Chawla Complex, Vikas Marg, Shakarpur, New Delhi-110092 (Delhi)  
Phone: +91 011 22546181, Mobile: +91 9818433797, +91 8882710429, Fax: +91 011 22546181  
E-Mail: gopalkeshri@yahoo.com

### **LIMITED REVIEW REPORT**

To,  
Board of Directors of  
M/S Citurgia Biochemicals Limited

We have reviewed the accompanying statement of Unaudited Financial Results of **M/S Citurgia Biochemicals Limited** (the "Company"), for the quarter and period ended 30<sup>th</sup> September 2019, being submitted by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement is the responsibility of the Companies Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditors of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus accordingly, we do not express and\ audit opinion.

Based on our review conducted as above, nothing has come to our attention that caused us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued hereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and disclosed Requirements) Regulations, 2015 and SEBI circular dated 5<sup>th</sup> July 2016 including the manner in which it is to be disclosed, or that its contains any material misstatement.

For G.P.Keshri & Associates,  
Chartered Accountants



CA. Gopal Prasad Keshri  
Partner

FRN: 017251N

M.NO: 098476

UDIN: 20098476AAAAAE8370

Place: New Delhi